Secondary analysis of phase 3 MARIPOSA in untreated EGFR-mutated advanced NSCLC: amivantamab plus lazertinib vs osimertinib lengthened median time to symptomatic progression (43.6 vs 29.3 months; HR 0.69, 95% CI 0.57–0.83).
Secondary analysis
Nguyen et al. Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer